Reducing Mortality from Colorectal Cancer by Screening for Fecal Occult Blood

New England Journal of Medicine

Volumn 328, Issue 19, 1993, Pages 1365-1371

  Mandel, Jack S ^a   Bond, John H ^a   Church, Timothy R ^a   Snover, Dale C ^a   Bradley, G Mary ^a   Schuman, Leonard M ^b   Ederer, Fred ^b,c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c EMMES CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; FECES ANALYSIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD TEST; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; CONFIDENCE INTERVALS; FEMALE; FOLLOW-UP STUDIES; HUMAN; MALE; MIDDLE AGE; MINNESOTA; OCCULT BLOOD; SENSITIVITY AND SPECIFICITY; SUPPORT, U.S. GOV'T, P.H.S.; SURVIVAL RATE;

EID: 0027223762     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199305133281901     Document Type: Article

References (28)

1. Boring CC, Squires TS, Tong T Cancer statistics, 1993. CA Cancer J Clin 1993; 43:7-26
2. Weisburger JH Causes, relevant mechanisms, and prevention of large bowel cancer. Semin Oncol 1991; 18:316-336
3. Winawer SJ, Schottenfeld D, Flehinger BJ Colorectal cancer screening. J Natl Cancer Inst 1991; 83:243-253
4. Simon JB Occult blood screening for colorectal carcinoma: a critical review. Gastroenterology 1985; 88:820-837
5. Kewenter J, Bjork S, Haglind E, Smith L, Svanvik J, Ahren C Screening and rescreening for colorectal cancer: a controlled trial of fecal occult blood testing in 27,700 subjects. Cancer 1988; 62:645-651
6. Kewenter J, Asztely M, Engaras B, Haglund E, Svanvik J, Ahren C. A randomised trial of faecal occult blood testing for early detection of colorectal cancer: results of screening and rescreening of 51,325 subjects. In: Miller AB, Chamberlain J, Day NE, Hakama M, Prorok PC, eds. Cancer screening. Cambridge, England: Cambridge University Press, 1991:117-25.
7. Klaaborg K, Madsen MS, Sondergaard O, Kronborg O Participation in mass screening for colorectal cancer with fecal occult blood test. Scand J Gastroenterol 1986; 21:1180-1184
8. Kronborg O, Fenger C, Sondergaard O, Pedersen KM, Olsen J Initial mass screening for colorectal cancer with fecal occult blood test: a prospective randomized study at Funen in Denmark. Scand J Gastroenterol 1987; 22:677-686
9. Kronborg O, Fenger C, Olsen J, Bech K, Sondergaard O Repeated screening for colorectal cancer with fecal occult blood test: a prospective randomized study at Funen, Denmark. Scand J Gastroenterol 1989; 24:599-606
10. Kronborg O, Fenger C, Worm J, Causes of death during the first 5 years of a randomized trial of mass screening for colorectal cancer with fecal occult blood test. Scand J Gastroenterol 1992; 27:47-52
11. Hardcastle JD, Farrands PA, Balfour TW, Chamberlain J, Amar SS, Sheldon MG Controlled trial of faecal occult blood testing in the detection of colorectal cancer. Lancet 1983; 2:1-4
12. Hardcastle JD, Thomas WM, Chamberlain J, Randomised, controlled trial of faecal occult blood screening for colorectal cancer: results for first 107 349 subjects. Lancet 1989; 1:1160-1164
13. Gilbertsen VA, Church TR, Grewe FJ, The design of a study to assess occult-blood screening for colon cancer. J Chronic Dis 1980; 33:107-114
14. Mandel JS, Bond J, Snover D, et al. The University of Minnesota's Colon Cancer Control Study: design and progress to date. In: Chamberlain J, Miller AB, eds. Screening for gastrointestinal cancer. Toronto: Hans Huber, 1988:17-24.
15. Church TR, Mandel JS, Bond JH, et al. Colon Cancer Control Study: status and current issues. In: Miller AB, Chamberlain J, Day NE, Hakama M, Prorok PC, eds. Cancer screening. Cambridge, England: Cambridge University Press, 1991:83-105.
16. Gilbertsen VA, Williams SE, Schuman L, McHugh R Colonoscopy in the detection of carcinoma of the intestine. Surg Gynecol Obstet 1979; 149:877-878
17. Dukes CE The classification of cancer of the rectum. J Pathol Bacteriol 1932; 35:323-332
18. Turnbull RB Jr Cancer of the colon: the five- and ten-year survival rates following resection utilizing the isolation technique. Ann R Coll Surg Engl 1970; 46:243-250
19. Church TR, Ederer F, Mandel JS, Watt GD, Geisser MS Estimating the duration of ongoing prevention trials. Am J Epidemiol 1993; 137:797-810
20. Ederer F, Church TR, Mandel JS Samples sizes of prevention trials have been too small. Am J Epidemiol 1993; 137:787-796
21. Cutler SJ, Ederer F Maximum utilization of the life table method in analyzing survival. J Chronic Dis 1958; 8:699-712
22. SAS/STAT user's guide: volume 2, version 6, 4th ed. Cary, N.C.: SAS Institute, 1989.
23. Lan KKG, DeMets DL Discrete sequential boundaries for clinical trials. Biometrika 1983; 70:659-663
24. Lan KKG, Wittes J The B-value: a tool for monitoring data. Biometrics 1988; 44:579-585
25. Kin K, Demets DL Confidence intervals following group sequential tests in clinical trials. Biometrics 1987; 43:857-864
26. Cox DR Regression models and life-tables. J R Stat Soc [B] 1972; 34:187-202
27. National Center for Health Statistics. International classification of diseases, adapted for use in the United States. 8th rev. Washington, D.C.: Government Printing Office, 1967. (PHS publication no. 1693).
28. Gilliland F. Effect of treatment modalities on the outcome of a screening trial. (Masters thesis. Minneapolis: University of Minnesota, 1991).